Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx Corp demonstrated a solid financial position following successful refinancing activities, which secured up to $60 million in committed capital and extended debt maturity to 2031. In Q3, the company achieved revenue of $21.5 million, showcasing robust international growth and maintaining a strong gross margin of 75%, with full-year revenue increasing to $90.5 million from $83.8 million in 2024. Additionally, the introduction of the AeriSeal and CONVERT II strategies is expected to enhance patient eligibility for treatment, contributing to sustainable growth and improved profitability through effective cost management and operational stability.

Pulmonx Corp's financial performance for 2025 reveals a modest annual revenue growth of 8%, yet the fourth quarter experienced a decline in revenue to $22.6 million, indicating challenges in the U.S. market. The company also faced significant cash depletion, with total cash, cash equivalents, and marketable securities falling to $69.8 million, a decrease of approximately $32 million year over year, and an expected further decline of around $23 million in 2026. Additionally, with operating expenses at $120.8 million and a net loss of $54 million, the financial metrics highlight operational inefficiencies and underscore concerns about the company’s future stability and growth potential.